Navigation Links
BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
Date:5/28/2009

TURKU, Finland, May 28 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.

The open-label, dose-escalating study is designed to evaluate the safety, tolerability and pharmacokinetics of the locally administered (into the bladder) product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer and it is expected to be well tolerated.

"We are pleased to advance to clinical testing with the ProtoCure instillation solution," says Lasse Leino, CEO of BioCis Pharma. "It is our first oncology product to reach this important milestone and follows the initiation of two phase 2a studies with our leading anti-inflammatory product in patients with inflammatory skin disorders that we recently announced. The ProtoCure cancer drug holds great promise for patients suffering from superficial bladder cancer. We are committed to take the product quickly to more extensive clinical efficacy testing after this preliminary safety study. We expect to get results from this study by the first quarter of 2010."

Bladder cancer is the fourth most common cancer in men and tenth among women. In addition, the recurrence rate is high, being almost 70 % in patients with the non-invasive form of the cancer, where the malignancy is typically found in the surface layers of the bladder. Non-invasive bladder cancer is treated by urologists using local surgery and intravesical drug therapy administered directly into the bladder. Existing drug therapies often have undesirable side effects and limited efficacy.

BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Oy.

http://www.biocis.com

Contacts:

Dr. Lasse Leino, CEO, BioCis Pharma Ltd., mobile phone +358-40-849-4694, lasse.leino@biocis.com


'/>"/>
SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
2. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
3. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
4. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
5. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
6. PARI Pharmas Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
7. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
10. Tris Pharma Announces Acceptance of Its First Two NDAs
11. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/3/2017)... 2017  Opioid addiction and other drugs of abuse, ... and threatening outcomes, were problems taken on directly as ... that support them, met this week. This according to ... drugs of abuse, procalcitonin and acute kidney injury were ... 69th meeting in San Diego, CA. ...
Breaking Medicine Technology:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... the healthcare industry, made the 2017 Inc. 5000 with a three-year sales ... the nation’s fastest-growing private companies and comprises the most comprehensive look at America’s ...
(Date:8/23/2017)... Francisco, CA (PRWEB) , ... August 23, 2017 , ... ... proud to announce a new blog archive organized month-by-month. The new rotation of archived ... treatments. Local Bay Area residents searching information about hair transplantation can review details online ...
(Date:8/22/2017)... AREA, CA (PRWEB) , ... August 22, 2017 ... ... an accessible luxurious collection of unique masks and serums that perfectly fuse the ... skin care advancements, at the 2017 Indie Beauty Expo on August 23rd & ...
(Date:8/22/2017)... ... ... of the past six years, Lightning Labels has sent out a call for users of ... variety and creativity of their designs. Submissions this year were open from May 18 to ... announce the winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... , ... “Wilderness Voices”: a collection of poetry inspired by life on a ... of published author, Martha McKown, an ordained United Methodist minister with graduate degrees in ... when her older sisters studied High School literature. She loved the early English ...
Breaking Medicine News(10 mins):